Tokyo Medical University Hospital, Department of Dermatology, Tokyo, Japan.
Toho University Ohashi Medical Center, Department of Dermatology, Tokyo, Japan.
J Am Acad Dermatol. 2020 Jul;83(1):109-116. doi: 10.1016/j.jaad.2020.02.033. Epub 2020 Mar 5.
Few effective treatments are available for male pattern hair loss (MPHL) or, especially, for female pattern hair loss (FPHL). Recently, cell-based therapies using autologous or allogeneic cells have been used clinically.
We examined the safety and efficacy of autologous cell-based therapy using dermal sheath cup (DSC) cells to treat MPHL and FPHL.
DSCs dissected from occipital hair follicles were cultured to manufacture DSC cells. Participants with MPHL or FPHL received single injections of 7.5 × 10, 1.5 × 10, or 3.0 × 10 DSC cells or a placebo in 4 randomized separate regions on the scalp, and hair densities and diameters were measured for 3, 6, 9, and 12 months.
Fifty men and 15 women aged 33 to 64 years were injected with DSC cells. Total hair density and cumulative hair diameter at the 3.0 × 10 DSC cells injection site was significantly increased compared with the placebo after 6 and 9 months. Men and women showed similar improvements, and there were no serious adverse events.
No lower cell numbers were tested, and the positive effect was temporary until 9 months.
The results suggest that cell therapy with autologous DSC cells may be useful as a new therapeutic method for treating MPHL and FPHL.
目前针对男性型脱发（MPHL）或女性型脱发（FPHL），有效的治疗方法寥寥无几。最近，临床已开始使用基于细胞的自体或同种异体细胞疗法。
我们评估了使用真皮鞘杯（DSC）细胞进行自体细胞治疗治疗 MPHL 和 FPHL 的安全性和有效性。
从枕部毛囊中分离出 DSCs 进行培养，以制造 DSC 细胞。MPHL 或 FPHL 参与者在头皮的 4 个随机分开的区域接受 7.5×10、1.5×10 或 3.0×10 DSC 细胞或安慰剂的单次注射，分别在 3、6、9 和 12 个月测量毛发密度和直径。
50 名年龄在 33 至 64 岁的男性和 15 名女性接受了 DSC 细胞注射。与安慰剂相比，在 6 个月和 9 个月时，3.0×10 DSC 细胞注射部位的总毛发密度和累积毛发直径明显增加。男性和女性均显示出相似的改善，且无严重不良事件。
未测试较低的细胞数量，且阳性效果仅持续至 9 个月。
结果表明，自体 DSC 细胞治疗可能是治疗 MPHL 和 FPHL 的一种新的治疗方法。
